1
|
Tsang TS and Gersh BJ: Atrial
fibrillation: An old disease, a new epidemic. Am J Med.
113:432–435. 2002.PubMed/NCBI View Article : Google Scholar
|
2
|
Schotten U, Neuberger HR and Allessie MA:
The role of atrial dilatation in the domestication of atrial
fibrillation. Prog Biophys Mol Biol. 82:151–162. 2003.PubMed/NCBI View Article : Google Scholar
|
3
|
Chang SL, Chen YC, Chen YJ, Wangcharoen W,
Lee SH, Lin CI and Chen SA: Mechanoelectrical feedback regulates
the arrhythmogenic activity of pulmonary veins. Heart. 93:82–88.
2007.PubMed/NCBI View Article : Google Scholar
|
4
|
Sanders P, Morton JB, Davidson NC, Spence
SJ, Vohra JK, Sparks PB and Kalman JM: Electrical remodeling of the
atria in congestive heart failure: Electrophysiological and
electroanatomic mapping in humans. Circulation. 108:1461–1468.
2003.PubMed/NCBIPubMed/NCBI
|
5
|
Li D, Melnyk P, Feng J, Wang Z, Petrecca
K, Shrier A and Nattel S: Effects of experimental heart failure on
atrial cellular and ionic electrophysiology. Circulation.
101:2631–2638. 2000.PubMed/NCBI View Article : Google Scholar
|
6
|
Yeh YH, Wakili R, Qi XY, Chartier D,
Boknik P, Kääb S, Ravens U, Coutu P, Dobrev D and Nattel S:
Calcium-handling abnormalities underlying atrial arrhythmogenesis
and contractile dysfunction in dogs with congestive heart failure.
Circ Arrhythm Electrophysiol. 1:93–102. 2008.PubMed/NCBI View Article : Google Scholar
|
7
|
Knight W and Yan C: Therapeutic potential
of PDE modulation in treating heart disease. Future Med Chem.
5:1607–1620. 2013.PubMed/NCBI View Article : Google Scholar
|
8
|
Miller CL and Yan C: Targeting cyclic
nucleotide phosphodiesterase in the heart: Therapeutic
implications. J Cardiovasc Transl Res. 3:507–515. 2010.PubMed/NCBI View Article : Google Scholar
|
9
|
Jaski BE, Fifer MA, Wright RF, Braunwald E
and Colucci WS: Positive inotropic and vasodilator actions of
milrinone in patients with severe congestive heart failure.
Dose-response relationships and comparison to nitroprusside. J Clin
Invest. 75:643–649. 1985.PubMed/NCBI View Article : Google Scholar
|
10
|
Omori K and Kotera J: Overview of PDEs and
their regulation. Circ Res. 100:309–327. 2007.PubMed/NCBI View Article : Google Scholar
|
11
|
Varma A, Shah KB and Hess ML:
Phosphodiesterase inhibitors, congestive heart failure, and sudden
death: Time for re-evaluation. Congest. Heart Fail. 18:229–233.
2012.PubMed/NCBI View Article : Google Scholar
|
12
|
Ghosh R, Sawant O, Ganpathy P, Pitre S and
Kadam VJ: Phosphodiesterase inhibitors: Their role and
implications. Int J PharmTech Res. 1:1148–1160. 2009.
|
13
|
Cuffe MS, Califf RM, Adams KF Jr, Benza R,
Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, et
al: Outcomes of a prospective trial of intravenous milrinone for
exacerbations of chronic heart failure (OPTIME-CHF) Investigators.
Short term intravenous milrinone for acute exacerbation of chronic
heart failure: A randomized controlled trial. JAMA. 287:1541–1547.
2002.PubMed/NCBI View Article : Google Scholar
|
14
|
Wechsler J, Choi YH, Krall J, Ahmad F,
Manganiello VC and Movsesian MA: Isoforms of cyclic nucleotide
phosphodiesterase PDE3A in cardiac myocytes. J Biol Chem.
277:38072–38078. 2002.PubMed/NCBI View Article : Google Scholar
|
15
|
Bevan S, Porteous L, Sitzer M and Markus
HS: Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic
carotid atherosclerosis. Stroke. 36:949–953. 2005.PubMed/NCBI View Article : Google Scholar
|
16
|
Milton AG, Aykanat VM, Hamilton-Bruce MA,
Nezic M, Jannes J and Koblar SA: Association of the
phosphodiesterase 4D (PDE4D) gene and cardioembolic stroke in an
Australian cohort. Int J Stroke. 6:480–486. 2011.PubMed/NCBI View Article : Google Scholar
|
17
|
Calverley PM, Rabe KF, Goehring UM,
Kristiansen S, Fabbri LM and Martinez FJ: Roflumilast in
symptomatic chronic obstructive pulmonary disease: Two randomised
clinical trials. Lancet. 374:685–694. 2009.PubMed/NCBI View Article : Google Scholar
|
18
|
Chiang CE, Luk HN, Wang TM and Ding PY:
Effects of sildenafil on cardiac repolarization. Cardiovasc Res.
55:290–299. 2002.PubMed/NCBI View Article : Google Scholar
|
19
|
Dustan Sarazan R, Crumb WJ Jr, Beasley CM
Jr, Emmick JT, Ferguson KM, Strnat CA and Sausen PJ: Absence of
clinically important HERG channel blockade by three compounds that
inhibit phosphodiesterase-5-sildenafil, tadalafil, and vardenafil.
Eur J Pharmacol. 502:163–167. 2004.PubMed/NCBI View Article : Google Scholar
|
20
|
Swissa M, Ohara T, Lee MH, Kaul S, Shah
PK, Hayashi H, Chen PS and Karagueuzian HS: Sildenafil-nitric oxide
donor combination promotes ventricular tachyarrhythmias in the
swine right ventricle. Am J Physiol Heart Circ Physiol.
282:H1787–H1792. 2002.PubMed/NCBI View Article : Google Scholar
|
21
|
Chen YJ and Chen SA: Electrophysiology of
pulmonary veins. J Cardiovasc Electrophysiol. 17:220–224.
2006.PubMed/NCBI View Article : Google Scholar
|
22
|
Honjo H, Boyett MR, Niwa R, Inada S,
Yamamoto M, Mitsui K, Horiuchi T, Shibata N, Kamiya K and Kodama I:
Pacing-induced spontaneous activity in myocardial sleeves of
pulmonary veins after treatment with ryanodine. Circulation.
107:1937–1943. 2003.PubMed/NCBI View Article : Google Scholar
|
23
|
Patterson E, Lazzara R, Szabo B, Liu H,
Tang D, Li YH, Scherlag BJ and Po SS: Sodium-calcium exchange
initiated by the Ca2+ transient: An arrhythmia trigger within
pulmonary veins. J Am Coll Cardiol. 47:1196–1206. 2006.PubMed/NCBI View Article : Google Scholar
|
24
|
Chen SA, Hsieh MH, Tai CT, Tsai CF,
Prakash VS, Yu WC, Hsu TL, Ding YA and Chang MS: Initiation of
atrial fibrillation by ectopic beats originating from the pulmonary
veins: Electrophysiological characteristics, pharmacological
responses, and effects of radiofrequency ablation. Circulation.
100:1879–1886. 1999.PubMed/NCBI View Article : Google Scholar
|
25
|
Chen YJ, Chen SA, Chen YC, Yeh HI, Chan P,
Chang MS and Lin CI: Effects of rapid atrial pacing on the
arrhythmogenic activity of single cardiomyocytes from pulmonary
veins: Implication in initiation of atrial fibrillation.
Circulation. 104:2849–2854. 2001.PubMed/NCBI View Article : Google Scholar
|
26
|
Lu YY, Lin YK, Wen ZH, Chen YC, Chen SA
and Chen YJ: Latrunculin B modulates electrophysiological
characteristics and arrhythmogenesis in pulmonary vein
cardiomyocytes. Clin Sci. 130:721–732. 2016.PubMed/NCBI View Article : Google Scholar
|
27
|
Chang SL, Hsiao YW, Tsai YN, Lin SF, Liu
SH, Lin YJ, Lo LW, Chung FP, Chao TF, Hu YF, et al: Interleukin-17
enhances cardiac ventricular remodeling via activating MAPK pathway
in ischemic heart failure. J Mol Cell Cardiol. 122:69–79.
2018.PubMed/NCBI View Article : Google Scholar
|
28
|
Pelizzo G, Avanzini MA, Icaro Cornaglia A,
Osti M, Romano P, Avolio L, Maccario R, Dominici M, De Silvestri A,
Andreatta E, et al: Mesenchymal stromal cells for cutaneous wound
healing in a rabbit model: Pre-clinical study applicable in the
pediatric surgical setting. J Transl Med. 13(219)2015.PubMed/NCBI View Article : Google Scholar
|
29
|
Lu YY, Cheng CC, Wu HJ, Lin YK, Chen YC,
Chen SA and Chen YJ: Effects of ANP on pulmonary vein
electrophysiology, Ca2+ homeostasis and adrenergic arrhythmogenesis
via PKA. Clin Exp Pharmacol Physiol. 47:247–254. 2020.PubMed/NCBI View Article : Google Scholar
|
30
|
Rieg AD, Suleiman S, Perez-Bouza A,
Braunschweig T, Spillner JW, Schröder T, Verjans E, Schälte G,
Rossaint R, Uhlig S and Martin C: Milrinone relaxes pulmonary veins
in guinea pigs and humans. PLoS One. 9(e87685)2014.PubMed/NCBI View Article : Google Scholar
|
31
|
Kato R, Sato J and Nishino T: Milrinone
decreases both pulmonary arterial and venous resistances in the
hypoxic dog. Br J Anaesth. 81:920–924. 1998.PubMed/NCBI View Article : Google Scholar
|
32
|
Vinogradova TM, Sirenko S, Lukyanenko YO,
Yang D, Tarasov KV, Lyashkov AE, Varghese NJ, Li Y, Chakir K, Ziman
B and Lakatta EG: Basal spontaneous firing of rabbit sinoatrial
node cells is regulated by dual activation of PDEs
(Phosphodiesterases) 3 and 4. Circ Arrhythm Electrophysiol.
11(e005896)2018.PubMed/NCBI View Article : Google Scholar
|
33
|
Van Wagoner DR and Lindsay BD:
Phosphodiesterase-4 activity: A critical modulator of atrial
contractility and arrhythmogenesis. J Am Coll Cardiol.
59:2191–2192. 2012.PubMed/NCBI View Article : Google Scholar
|
34
|
Lu Z, Xu X, Hu X, Lee S, Traverse JH, Zhu
G, Fassett J, Tao Y, Zhang P, dos Remedios C, et al: Oxidative
stress regulates left ventricular PDE5 expression in the failing
heart. Circulation. 121:1474–1483. 2010.PubMed/NCBI View Article : Google Scholar
|
35
|
Nagendran J, Archer SL, Soliman D, Gurtu
V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB,
et al: Phosphodiesterase type 5 is highly expressed in the
hypertrophied human right ventricle, and acute inhibition of
phosphodiesterase type 5 improves contractility. Circulation.
116:238–248. 2007.PubMed/NCBI View Article : Google Scholar
|
36
|
Hwang IC, Kim YJ, Park JB, Yoon YE, Lee
SP, Kim HK, Cho GY and Sohn DW: Pulmonary hemodynamics and effects
of phosphodiesterase type 5 inhibition in heart failure: A
meta-analysis of randomized trials. BMC Cardiovasc Disord.
17(150)2017.PubMed/NCBI View Article : Google Scholar
|
37
|
Lin YK, Lu YY, Chen YC, Chen YJ and Chen
SA: Nitroprusside modulates pulmonary vein arrhythmogenic activity.
J Biomed Sci. 17(20)2010.PubMed/NCBI View Article : Google Scholar
|
38
|
Isidori AM, Cornacchione M, Barbagallo F,
et al: Inhibition of type 5 phosphodiesterase counteracts
β2-adrenergic signalling in beating cardiomyocytes. Cardiovasc Res.
106:408–420. 2015.PubMed/NCBI View Article : Google Scholar
|